drugset / Trial / NCT01077362

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

NCT01077362

Phase 3 Completed 312 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy (improvement of signs and symptoms) and safety of ustekinumab in patients with psoriatic arthritis.

Timeline

Start
2010-03
Primary completion
2012-03
Completion
2012-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ustekinumab Monoclonal antibody 45 mg Subcutaneous
Subject Ustekinumab Monoclonal antibody 90 mg Subcutaneous

Indications